Heteroplasmic mtDNA mutations may be present at different levels in different tissues. Affected organs or tissues (e.g., brain, muscle) may have higher mutant levels than blood. Since blood is readily accessible for minimally invasive testing, it is important to be able to detect low mutant levels in blood that may indicate higher levels in affected organs or issues. The MitoDx test utilizes proprietary Next Generation Sequencing (NGS) methods to accurately measure mtDNA heteroplasmy at frequencies that are below the threshold of detection by other diagnostic methods. Thus, MitoDx testing of a patient's blood sample may reveal disease affecting other organs or tissues. MEDomics' proprietary NGS and bioinformatics methods have set the industry standard for the most sensitive and accurate detection of mitochondrial DNA mutations.
Why Physicians should Partner